Search This Blog

Thursday, September 17, 2026

Nuvation positive efficacy data for lung cancer

 

Nuvation Bio's TRUST-I and TRUST-II subgroup data show IBTROZI delivers consistent, durable efficacy in advanced ROS1-positive NSCLC

  • Subgroup analyses include prior-chemotherapy and ROS1 fusion-partner subgroups in advanced ROS1-positive NSCLC patients
  • Results reinforce IBTROZI (taletrectinib) use across a broad advanced ROS1-positive NSCLC patient population
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)